MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mazzoni, M. R.
Right arrow Articles by Hamm, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazzoni, M. R.
Right arrow Articles by Hamm, H. E.

Vol. 58, Issue 1, 226-236, July 2000

A Galpha s Carboxyl-Terminal Peptide Prevents Gs Activation by the A2A Adenosine Receptor

Maria R. Mazzoni, Simone Taddei, Laura Giusti, Paolo Rovero, Claudia Galoppini, Annamaria D'Ursi, Stefania Albrizio, Antonio Triolo, Ettore Novellino, Giovanni Greco, Antonio Lucacchini, and Heidi E. Hamm

Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Università di Pisa, Pisa, Italy (M.R.M., S.T., L.G., A.L.); Dipartimento di Scienze Farmaceutiche, Università di Salerno, Salerno, Italy (P.R., A.D., S.A.); Dipartimento di Chimica Farmaceutica e Tossicologica, Università di Napoli "Federico II", Napoli, Italy (E.N., G.G.); Istituto di Mutagenesi e Differenziamento, Peptide Synthesis Lab, Consiglio Nazionale delle Ricerche, Pisa, Italy (C.G.); Menarini Ricerche, Firenze, Italy (A.T.); and Northwestern University Institute for Neuroscience, Department of Molecular Pharmacology and Biological Chemistry, Chicago, Illinois (H.E.H.)

The molecular mechanisms of interaction between Gs and the A2A adenosine receptor were investigated using synthetic peptides corresponding to various segments of the Galpha s carboxyl terminus. Synthetic peptides were tested for their ability to modulate binding of a selective radiolabeled agonist, [3H]2-[4-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine ([3H]CGS21680), to A2A adenosine receptors in rat striatal membranes. The Galpha s peptides stimulated specific binding both in the presence and absence of 100 µM guanosine-5'-O-(3-thiotriphosphate) (GTPgamma S). Three peptides, Galpha s(378-394)C379A, Galpha s(376-394)C379A, and Galpha s(374-394)C379A, were the most effective. In the presence of GTPgamma S, peptide Galpha s(374-394)C379A increased specific binding in a dose-dependent fashion. However, the peptide did not stabilize the high-affinity state of the A2A adenosine receptor for [3H]CGS21680. Binding assays with a radiolabeled selective antagonist, [3H]5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine ([3H]SCH58261), showed that the addition of the Galpha s peptide modified the slope of the 5'-N-ethylcarboxamidoadenosine (NECA) competition curve, suggesting modulation of receptor affinity states. In the presence of GTPgamma S, the displacement curve was right-shifted, whereas the addition of Galpha s(374-394)C379A caused a partial left-shift. Both curves were fitted by one-site models. This same Galpha s peptide was also able to disrupt Gs-coupled signal transduction as indicated by inhibition of the A2A receptor-stimulated adenylyl cyclase activity without affecting either basal or forskolin-stimulated enzymatic activity in the same membrane preparations. Shorter peptides from Galpha s and Galpha i1/2 carboxyl termini were not effective. NMR spectroscopy showed the strong propensity of peptide Galpha s(374-394)C379A to assume a compact carboxyl-terminal alpha -helical conformation in solution. Overall, our results point out the conformation requirement of Galpha s carboxyl-terminal peptides to modulate agonist binding to rat A2A adenosine receptors and disrupt signal transduction.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J.-S. Huang, L. Dong, T. Kozasa, and G. C. Le Breton
Signaling through G{alpha}13 Switch Region I Is Essential for Protease-activated Receptor 1-mediated Human Platelet Shape Change, Aggregation, and Secretion
J. Biol. Chem., April 6, 2007; 282(14): 10210 - 10222.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. M. D'Ursi, L. Giusti, S. Albrizio, F. Porchia, C. Esposito, G. Caliendo, C. Gargini, E. Novellino, A. Lucacchini, P. Rovero, et al.
A Membrane-Permeable Peptide Containing the Last 21 Residues of the G{alpha}S Carboxyl Terminus Inhibits GS-Coupled Receptor Signaling in Intact Cells: Correlations between Peptide Structure and Biological Activity
Mol. Pharmacol., March 1, 2006; 69(3): 727 - 736.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Mollereau, H. Mazarguil, J.-M. Zajac, and M. Roumy
Neuropeptide FF (NPFF) Analogs Functionally Antagonize Opioid Activities in NPFF2 Receptor-Transfected SH-SY5Y Neuroblastoma Cells
Mol. Pharmacol., March 1, 2005; 67(3): 965 - 975.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. F. Schwindinger, K. E. Giger, K. S. Betz, A. M. Stauffer, E. M. Sunderlin, L. J. Sim-Selley, D. E. Selley, S. K. Bronson, and J. D. Robishaw
Mice with Deficiency of G Protein {gamma}3 Are Lean and Have Seizures
Mol. Cell. Biol., September 1, 2004; 24(17): 7758 - 7768.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. S. Feldman, A. M. Zamah, K. L. Pierce, W. E. Miller, F. Kelly, A. Rapacciuolo, H. A. Rockman, W. J. Koch, and L. M. Luttrell
Selective Inhibition of Heterotrimeric Gs Signaling. TARGETING THE RECEPTOR-G PROTEIN INTERFACE USING A PEPTIDE MINIGENE ENCODING THE Galpha s CARBOXYL TERMINUS
J. Biol. Chem., August 2, 2002; 277(32): 28631 - 28640.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. S. Weinstein, S. Yu, D. R. Warner, and J. Liu
Endocrine Manifestations of Stimulatory G Protein {alpha}-Subunit Mutations and the Role of Genomic Imprinting
Endocr. Rev., October 1, 2001; 22(5): 675 - 705.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics